CAR-T cancer therapy is here: Here's how it works
A revolution in cancer therapy was approved by the FDA this week. Novartis' Kymriah (tisagenlecleucel), formerly known as CTL019, was approved for relapsing B-cell acute lymphoblastic leukemia (ALL) in children and young adults on Monday. Concerns about price and access have naturally arisen. Understanding why this truly individualized breakthrough therapy costs more may lie in understanding the complexity in its manufacturing for a population of 1. Check this graphic from Labiotech.EU.